Lucid Free Cash Flow Per Share vs End Period Cash Flow Analysis
| LUCD Stock | USD 0.98 0.02 2.00% |
Lucid Diagnostics financial indicator trend analysis is infinitely more than just investigating Lucid Diagnostics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lucid Diagnostics is a good investment. Please check the relationship between Lucid Diagnostics Free Cash Flow Per Share and its End Period Cash Flow accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lucid Diagnostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.
Free Cash Flow Per Share vs End Period Cash Flow
Free Cash Flow Per Share vs End Period Cash Flow Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lucid Diagnostics Free Cash Flow Per Share account and End Period Cash Flow. At this time, the significance of the direction appears to have pay attention.
The correlation between Lucid Diagnostics' Free Cash Flow Per Share and End Period Cash Flow is -0.73. Overlapping area represents the amount of variation of Free Cash Flow Per Share that can explain the historical movement of End Period Cash Flow in the same time period over historical financial statements of Lucid Diagnostics, assuming nothing else is changed. The correlation between historical values of Lucid Diagnostics' Free Cash Flow Per Share and End Period Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow Per Share of Lucid Diagnostics are associated (or correlated) with its End Period Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when End Period Cash Flow has no effect on the direction of Free Cash Flow Per Share i.e., Lucid Diagnostics' Free Cash Flow Per Share and End Period Cash Flow go up and down completely randomly.
Correlation Coefficient | -0.73 |
| Relationship Direction | Negative |
| Relationship Strength | Weak |
Free Cash Flow Per Share
The amount of cash a company generates after accounting for capital expenditures, divided by the number of outstanding shares. It represents the cash available for dividends, share buybacks, or debt repayment per share.End Period Cash Flow
Most indicators from Lucid Diagnostics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lucid Diagnostics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lucid Diagnostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.The current year's Issuance Of Capital Stock is expected to grow to about 17.1 M, whereas Selling General Administrative is forecasted to decline to about 13.1 M.
Lucid Diagnostics fundamental ratios Correlations
Click cells to compare fundamentals
Lucid Diagnostics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Lucid Diagnostics fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Current Liabilities | 6.3M | 15.7M | 4.3M | 8.4M | 29.4M | 30.9M | |
| Net Tangible Assets | (5.3M) | (13.5M) | (24.1M) | 19.6M | 22.5M | 23.7M | |
| Retained Earnings | (5.5M) | (13.8M) | (41.9M) | (98.1M) | (150.7M) | (143.2M) | |
| Accounts Payable | 799.1K | 2.1M | 1.5M | 1.1M | 1.1M | 1.3M | |
| Total Current Assets | 390.9K | 1.4M | 57.3M | 24.4M | 22.1M | 19.4M | |
| Common Stock | 14.1K | 14.1K | 35K | 41K | 42K | 28.6K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Lucid Diagnostics is a strong investment it is important to analyze Lucid Diagnostics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Lucid Diagnostics' future performance. For an informed investment choice regarding Lucid Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lucid Diagnostics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lucid Diagnostics. If investors know Lucid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lucid Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.12) | Revenue Per Share 0.09 | Quarterly Revenue Growth 0.497 | Return On Assets (1.01) | Return On Equity (10.08) |
The market value of Lucid Diagnostics is measured differently than its book value, which is the value of Lucid that is recorded on the company's balance sheet. Investors also form their own opinion of Lucid Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Lucid Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lucid Diagnostics' market value can be influenced by many factors that don't directly affect Lucid Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lucid Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lucid Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lucid Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.